Usefulness of a multiplex immunodot in case of discordant results between automated COVID-19 serological assays

•We challenged the performance of a new pan-IgG Immunoassay, namely COVIDOT-TEST, in the case of discordant serological results on fully automated analyzers.•38 serum samples from recovered COVID-19 subjects with discordant serological results on Roche and Snibe platforms, were collected.•Data confirmed an immune response against different SARS-CoV-2 specific antigens using the pan-IgG immunodoassay kit.•All samples showed specific IgG reactions on ≥ 2 different antigens on immunodot strips.•Our preliminary study showed that the new pan-IgG Immunoassay is a reliable assay to confirm suspicious COVID-19 serological screening results. At present, the only reliable test for COVID-19 diagnosis is RT-qPCR. Serological assays have been widely used to increase the detection sensitivity of infected population. Hereby, we report the performance of a new pan-IgG multiplex Enzyme Immunoassay (immunodot) method for exploration of discrepant SARS-COV-2 serological results. A retrospective study on 38 residual serum samples from recovered COVID-19 subjects with discordant serological results on Roche and Snibe platforms, were reanalyzed on a new semi-automated pan-IgG immunodot Enzyme Immunoassay, namely COVIDOT-TEST, in order to find the source of discrepancies and to evaluate the latter method. All samples were analyzed on the BlueDiver® Instrument and all strips were read by the BlueScan® Scanner using Dr DOT® Software. Results: Based on our data, subject samples showed specific IgG reactions on ≥ 2 different antigens on immunodot strips. Of these 38 samples, 97.4 % of samples showed specific IgG reaction against S1 + S2 antigens, 89.5 % showed against RBD antigen, 86.8 % against S2 antigen reaction on the COVIDOT-TEST kit. Specific IgG-S1 antigen and IgG-N antigen reactions were detected in 73.7 % and 65.8 % of the samples, respectively. The new semi-automated pan-IgG immunodot Enzyme Immunoassay method appeared to be a reliable assay to confirm suspicious COVID-19 serological screening results.